Latest Breaking News On - Company trappsol - Page 4 : comparemela.com

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Cyclo Therapeutics, Inc. , a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today. | June 5, 2023

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing

GAINESVILLE, Fla. (BUSINESS WIRE) Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has entere.

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Company on track to complete enrollment in ongoing pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 by year end 2023 . | May 15, 2023

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

Cyclo Therapeutics (CYTH) Provides Clinical Program Update and Highlights Recent Achievements